Trial Profile
A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase HPV Vaccine Utilization and Adherence Among College Students in Eastern North Carolina.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Cervical cancer; Genital warts; Human papillomavirus infections; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 13 Apr 2012 New trial record